A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

Clinical trial NCT07382739 · RECRUITING

Trial details

NCT number: NCT07382739
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Phase 2 Radiotherapy-Induced Immune Priming Elranatamab Relapsed Refractory Multiple Myeloma (RRMM)Extramedullary Disease in Multiple Myeloma Paramedullary Disease PMD

Start date: 2026-03-31
Primary completion: 2028-12-31
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.